Mind & Matter cover image

Psychedelic Startups, Biotech, Drug Discovery, Psilocybin, DMT, Psychedelics & Society | Sam Banister | 79

Mind & Matter

00:00

Silosiben

We're not doing silis ibon, or any natural psychelix as such. We are looking at using a number of innovative a medicinal chemistry approaches to actually modifying first generation psychodelics in a more dramatic way. Our hypothesis here is that we'll get different target receptory engagements, which we've already demonstrated for a number of these compounds, and that that will lead to a different benefits in the clinic.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app